middle.news
Invex Therapeutics Reports $1.35M Loss as Alzheimer’s Research Intensifies
7:17pm on Monday 31st of August, 2026 AEST
•
Healthcare
Read Story
Invex Therapeutics Reports $1.35M Loss as Alzheimer’s Research Intensifies
7:17pm on Monday 31st of August, 2026 AEST
Key Points
Net loss widened to $1.35 million in FY2026
R&D spend more than doubled, focused on Exenatide for neurological conditions
Collaboration with Tessara Therapeutics expanded Alzheimer’s preclinical studies
Orphan drug designation for Traumatic Brain Injury renewed in Europe
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Invex Therapeutics (ASX:IXC)
OPEN ARTICLE